Literature DB >> 18779599

Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia.

Asher A Chanan-Khan, Amy Whitworth, Naveen Bangia, Carl W Porter, Kelvin Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18779599     DOI： 10.1200/JCO.2008.18.2857

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug.

Authors:  Alan G Ramsay; John G Gribben
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941

2.  Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.

Authors:  Rachid Baz; Mehul Patel; Elizabeth Finley-Oliver; Daniel Lebovic; Mohamad A Hussein; Kena C Miller; Margaret Wood; Taimur Sher; Kelvin Lee; Asher A Chanan-Khan
Journal:  Leuk Lymphoma       Date:  2010-06

3.  Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.

Authors:  Stacey L Berg; Mitchell S Cairo; Heidi Russell; Janet Ayello; Ashish Mark Ingle; Henry Lau; Nianhang Chen; Peter C Adamson; Susan M Blaney
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

Review 4.  Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2008-11-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.